Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 1
2009 1
2014 1
2015 1
2016 2
2017 2
2018 1
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
James E, Ellis C, Brassington R, Sathasivam S, Young CA. James E, et al. Cochrane Database Syst Rev. 2022 May 20;5(5):CD006981. doi: 10.1002/14651858.CD006981.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593746 Free PMC article. Review.
BACKGROUND: Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS), is a progressive neurodegenerative condition that may cause dysphagia, as well as limb weakness, dysarthria, emotional lability, and respiratory failure. ...The trial p …
BACKGROUND: Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS), is a progressive neurodegene …
Prevalence of depression among amyotrophic lateral sclerosis (ALS) patients: A systematic review and meta-analysis.
Heidari ME, Nadali J, Parouhan A, Azarafraz M, Tabatabai SM, Irvani SSN, Eskandari F, Gharebaghi A. Heidari ME, et al. J Affect Disord. 2021 May 15;287:182-190. doi: 10.1016/j.jad.2021.03.015. Epub 2021 Mar 12. J Affect Disord. 2021. PMID: 33799036 Review.
BACKGROUND: Amyotrophic lateral sclerosis (ALS) people have a high risk of severe mental disorders, like depression, which impacts their function, quality of life, and mobility. ...Subgroup analyses are performed on the severity of depression, instruments of …
BACKGROUND: Amyotrophic lateral sclerosis (ALS) people have a high risk of severe mental disorders, like depression, wh …
Pain in amyotrophic lateral sclerosis.
Chiò A, Mora G, Lauria G. Chiò A, et al. Lancet Neurol. 2017 Feb;16(2):144-157. doi: 10.1016/S1474-4422(16)30358-1. Epub 2016 Dec 8. Lancet Neurol. 2017. PMID: 27964824 Free article. Review.
Pain is a largely neglected symptom in patients with amyotrophic lateral sclerosis (ALS) although it is reported by most of these patients. ...In the later stages of ALS, pain can be severe enough to require increased use of sedative and analgesic drugs, and …
Pain is a largely neglected symptom in patients with amyotrophic lateral sclerosis (ALS) although it is reported by mos …
Epidemiological evidence that physical activity is not a risk factor for ALS.
Hamidou B, Couratier P, Besançon C, Nicol M, Preux PM, Marin B. Hamidou B, et al. Eur J Epidemiol. 2014 Jul;29(7):459-75. doi: 10.1007/s10654-014-9923-2. Epub 2014 Jul 2. Eur J Epidemiol. 2014. PMID: 24986107 Review.
To elucidate whether physical activity (PA) and sport increase the risk of developing amyotrophic lateral sclerosis (ALS), a literature review of epidemiological studies was conducted according to the Meta-analysis of Observational Studies in Epidemiology gui …
To elucidate whether physical activity (PA) and sport increase the risk of developing amyotrophic lateral sclerosis (AL …
Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
Long C, Amoasii L, Bassel-Duby R, Olson EN. Long C, et al. JAMA Neurol. 2016 Nov 1;73(11):1349-1355. doi: 10.1001/jamaneurol.2016.3388. JAMA Neurol. 2016. PMID: 27668807 Free PMC article. Review.
EVIDENCE REVIEW: PubMed and Google Scholar were searched for articles published from June 30, 1989, through June 9, 2016, using the following keywords: genome editing, CRISPR-Cas9, neuromuscular disease, Duchenne muscular dystrophy, spinal muscular atrophy, amyotrophic …
EVIDENCE REVIEW: PubMed and Google Scholar were searched for articles published from June 30, 1989, through June 9, 2016, using the followin …
Alternative medicine therapies in neurological disorders: Prevalence, reasons and associated factors. A systematic review.
Soto-Lara M, Silva-Loredo M, Monroy-Córdoba JR, Flores-Ordoñez P, Cervera-Delgadillo NG, Carrillo-Mora P. Soto-Lara M, et al. Complement Ther Med. 2023 May;73:102932. doi: 10.1016/j.ctim.2023.102932. Epub 2023 Feb 15. Complement Ther Med. 2023. PMID: 36805318 Free article. Review.
Prevalence of CAM use was highly variable from one study to another (16% in stroke patients, to 100% in amyotrophic lateral sclerosis or spinal cord injury patients). ...CONCLUSIONS: The prevalence of CAM use in neurological diseases is highly variable …
Prevalence of CAM use was highly variable from one study to another (16% in stroke patients, to 100% in amyotrophic lateral …
Alzheimer's Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing.
Goldman JS, Van Deerlin VM. Goldman JS, et al. Mol Diagn Ther. 2018 Oct;22(5):505-513. doi: 10.1007/s40291-018-0347-7. Mol Diagn Ther. 2018. PMID: 29971646 Free PMC article. Review.
However, to interpret genetic results, clinicians require an understanding of the benefits and limitations of different genetic technologies, such as the inability to detect large repeat expansions in such diseases as C9orf72-associated FTD and amyotrophic lateral …
However, to interpret genetic results, clinicians require an understanding of the benefits and limitations of different genetic technologies …
Gene transfer in experimental medicine.
Romano G. Romano G. Drug News Perspect. 2003 Jun;16(5):267-76. doi: 10.1358/dnp.2003.16.5.829314. Drug News Perspect. 2003. PMID: 12942157 Review.
A phase I gene therapy clinical trial has recently been approved for the treatment of Parkinson's disease, while preclinical studies are in progress to develop gene-based interventions for the treatment of Alzheimer's disease and Huntington's disease, amyotrophic latera …
A phase I gene therapy clinical trial has recently been approved for the treatment of Parkinson's disease, while preclinical studies are in …
OPTN variants in ALS cases: a case report of a novel mutation and literature review.
Mou Y, Li M, Liu M, Wang J, Zhu G, Zha Y. Mou Y, et al. Neurol Sci. 2022 Sep;43(9):5391-5396. doi: 10.1007/s10072-022-06125-5. Neurol Sci. 2022. PMID: 35661277 Review.
INTRODUCTION: Optineurin (OPTN)-associated mutations have been implicated in the development of type 12 amyotrophic lateral sclerosis (ALS12). We reported a case of ALS with a new OPTN variant (p.D527fs) and reviewed relevant literature to better under …
INTRODUCTION: Optineurin (OPTN)-associated mutations have been implicated in the development of type 12 amyotrophic lateral …
14 results